Pediatr. praxi. 2022;23(5):359-360 | DOI: 10.36290/ped.2022.065

Proton pump inhibitors by children

MUDr. Pavel Frühauf, CSc.
Klinika pediatrie a dědičných poruch metabolismu, 1. LF UK a VFN, Praha

Proton pump inhibitors (PPI) remains important therapeutic option for esophagitis and gastritis. However recent studies demonstrate no benfit when prescribing PPIs for chronic cough, infantile reflux, asthma, or functional gastrointestinal disorders. Recent studies suggest averse effects on microbiome diversity and immune function, resulting in increased rate of gastrointestinal infections, bone fractures and atopic disorders.

Keywords: proton pump inhibitors, PPI, children.

Published: October 11, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Frühauf P. Proton pump inhibitors by children. Pediatr. praxi. 2022;23(5):359-360. doi: 10.36290/ped.2022.065.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Orel R, Benninga MA, Broekaert IJ, et al. Drugs in Focus: Proton Pump Inhibitors. J Pediatr Gastroenterol Nutr. 2021;72(5):645-653. Go to original source... Go to PubMed...
    2. Aznar-Lou I, Reilev M, Lødrup AB, et al. Use of proton pump inhibitors among Danish children: a 16-year register-based nationwide study. Basic Clin Pharmacol Toxicol. 2019; 124:704-710. Go to original source... Go to PubMed...
    3. De Bruyne P, Christiaens T, Vander Stichele R, et al. Changes in prescription patterns of acid-suppressant medications by Belgian pediatricians: analysis of the national database [1997-2009]. J Pediatr Gastroenterol Nutr. 2014;58:220-225. Go to original source... Go to PubMed...
    4. Barron JJ, Tan H, Spalding J, et al. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45:421-427. Go to original source... Go to PubMed...
    5. Kierkus J, Oracz G, Korczowski B, et al. Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease. Drug Saf. 2014;37:309-316. Go to original source... Go to PubMed...
    6. Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep. 2009;11:433-441. Go to original source... Go to PubMed...
    7. Hyams JS, Di Lorenzo C, Saps M, et al. Functional disorders: children and adolescents. Gastroenterology. 2016; S0016-5085(16)00181-5.
    8. Ng SM, Moore HS. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database Syst Rev. 2016. CD003424 doi: 10.1002/14651858.cd003424.pub2. Go to original source... Go to PubMed...
    9. Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13-22. Go to original source... Go to PubMed...
    10. Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:516-554. Go to original source... Go to PubMed...
    11. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;64:991-1003. Go to original source... Go to PubMed...
    12. Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65:524-531. Go to original source... Go to PubMed...
    13. Schwarzer A, Bontems P, Urruzuno P, et al. Sequential therapy for Helicobacter pylori infection in treatment-naïve children. Helicobacter. 2016;21:106-113. Go to original source... Go to PubMed...
    14. Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo M, et al. Long-term treatment with proton pump inhibitors is effective in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2018;67:210-216. Go to original source... Go to PubMed...
    15. Gibbons TE, Gold BD. The use of proton pump inhibitors in children. A comprehensive review. Pediatr Drugs. 2003; 5:25-40. Go to original source... Go to PubMed...
    16. Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci. 2012; 57:1413-1419. Go to original source... Go to PubMed...
    17. Tolia V, Bishop PR, Tsou VM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006; 42:384-391. Go to original source... Go to PubMed...
    18. Electronic Medicines Compendium. www.medicinces.org.uk/emc.
    19. Available from: www.medicinesforchildren.org.uk/omeprazole-gastro-oesophageal-reflux-disease-gord.
    20. Turk H, Hauser B, Brecelj J, et al. Effect of proton pump inhibition on acid, weakly acid and weakly alkaline gastro-esophageal reflux in children. World J Pediatr. 2013;9:36-41. Go to original source... Go to PubMed...
    21. Chang AB, Lasserson TJ, Kiljander TO, et al. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. 2006;332:11-17. Go to original source... Go to PubMed...
    22. De Bruyne P, Ito S. Toxicity of long-term use of proton pump inhibitors in children. Arch Dis Child. 2018;103:78-82. Go to original source... Go to PubMed...
    23. Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci. 2008;53(2):385-393. Go to original source... Go to PubMed...
    24. Freedberg DE, Lamousé-Smith ES, Lightdale JR, et al. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis. 2015;61:912-917. Go to original source... Go to PubMed...
    25. Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther. 2010;31:754-759. Go to original source... Go to PubMed...
    26. Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 200;117(5):e817-20. Go to PubMed...
    27. Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multi­center, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154:514-520. Go to original source... Go to PubMed...
    28. Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2010;50:609-618. Go to original source... Go to PubMed...
    29. Holbrook JT, Wise RA, Gold BD, et al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA. 2012;307:373-381. Go to original source... Go to PubMed...
    30. Drut R, Altamirano E, Cueto Rúa E. Omeprazole-associated changes in the gastric mucosa of children. J Clin Pathol. 2008;61:754-756. Go to original source... Go to PubMed...
    31. Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26:2501-2507. Go to original source... Go to PubMed...
    32. Freedberg DE, Haynes K, Denburg MR, Zemel BS, Leonard MB, Abrams JA, Yang YX. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26(10):2501-2507. Go to original source... Go to PubMed...
    33. Tighe MP, Afzal NA, Bevan A, et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr. Drugs. 2009;11:185-202. Go to original source... Go to PubMed...
    34. Ogawa R , Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509-533. Go to original source... Go to PubMed...
    35. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37:201-211. Go to original source... Go to PubMed...
    36. Pasquali SK, Yow E, Jennings LK, et al. Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease. Congenit Heart Dis. 2010;5:552-555. Go to original source... Go to PubMed...
    37. Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Proton pump inhibitor use and risk of depression and anxiety in children: nationwide cohort study. Clin Transl Sci. 2022;15(5):1112-1122. Go to original source... Go to PubMed...
    38. Stark CM, Susi A, Nierenberg AA, Nylund CM. Association of Early Life Prescriptions for Antibiotics and Acid Suppressants with Childhood Psychotropic Prescriptions. J Pediatr. 2022;246:191-198.e4. Go to original source... Go to PubMed...
    39. Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: Review of reported risks and controversies. Laryngoscope Investig Otolaryngol. 2018;3(6):457-462. Go to original source... Go to PubMed...
    40. Untersmayr E, Jensen-Jarolim E. The role of protein digestibility and antacids on food allergy outcomes. J Allergy Clin Immunol. 2008;121:1301-1308. Go to original source... Go to PubMed...
    41. Schöll I, Untersmayr E, Bakos N, et al. Antiulcer drugs promote oral sensitization and hypersensitivity to hazelnut allergens in BALB/c mice and humans. Am J Clin Nutr. 2005;81:154-160. Go to original source... Go to PubMed...
    42. Wang YH, et al. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children. JAMA Pediatr. 2021;175(4):394-403. Go to original source... Go to PubMed...
    43. Aggarwal N. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors. Drugs Real World Outcomes. 2016;3:145. Go to original source... Go to PubMed...
    44. Law EH, Badowski M, Hung YT, et al. Association Between Proton Pump Inhibitors and Microscopic Colitis. Ann Pharmacother. 2017;51:253. Go to original source... Go to PubMed...
    45. Xia B, Yang M, Nguyen LH, et al. Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts. Gastroenterology. 2021;161:1842. Go to original source... Go to PubMed...
    46. Xie Y, Bowe B, Li T, et al. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7:e015735. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.